300233 金城医药
已收盘 02-06 15:00:00
资讯
新帖
简况
股市必读：金城医药（300233）预计2025年全年归属净利润盈利4000万元至5300万元
证券之星 · 02-02
股市必读：金城医药（300233）预计2025年全年归属净利润盈利4000万元至5300万元
金城医药：预计2025年全年扣非后净利润盈利2800万元至3700万元
证券之星 · 01-30
金城医药：预计2025年全年扣非后净利润盈利2800万元至3700万元
金城医药（300233）披露签署权益许可和经销协议之补充协议，1月26日股价上涨2.91%
证券之星 · 01-26
金城医药（300233）披露签署权益许可和经销协议之补充协议，1月26日股价上涨2.91%
金城医药与Theramex深化合作，再获五款女性健康产品中国独家权益
中金财经 · 01-26
金城医药与Theramex深化合作，再获五款女性健康产品中国独家权益
金城医药最新公告：子公司金城金素收到注射用头孢呋辛钠药品补充申请批准通知书
中金财经 · 01-21
金城医药最新公告：子公司金城金素收到注射用头孢呋辛钠药品补充申请批准通知书
金城医药：截至2026年1月20日股东总户数为29,110户
证券之星 · 01-21
金城医药：截至2026年1月20日股东总户数为29,110户
金城医药控股股东金城实业质押展期，涉及178.64万股
中金财经 · 01-12
金城医药控股股东金城实业质押展期，涉及178.64万股
股市必读：金城医药（300233）1月8日董秘有最新回复
证券之星 · 01-09
股市必读：金城医药（300233）1月8日董秘有最新回复
金城医药(300233)12月31日股东户数2.77万户，较上期增加0.68%
证券之星 · 01-06
金城医药(300233)12月31日股东户数2.77万户，较上期增加0.68%
每周股票复盘：金城医药（300233）子公司补缴税款影响净利减少993.13万元
证券之星 · 01-03
每周股票复盘：金城医药（300233）子公司补缴税款影响净利减少993.13万元
金城医药（300233）披露签署《股权转让协议》之补充协议，12月30日股价下跌1.06%
证券之星 · 2025-12-30
金城医药（300233）披露签署《股权转让协议》之补充协议，12月30日股价下跌1.06%
金城医药最新公告：子公司金城泰尔收到药品GMP符合性检查告知书
证券之星 · 2025-12-30
金城医药最新公告：子公司金城泰尔收到药品GMP符合性检查告知书
金城医药：不存在退市风险警示情形
证券之星 · 2025-12-30
金城医药：不存在退市风险警示情形
金城医药最新公告：与傅苗青、周白水签署股权转让协议之补充协议
证券之星 · 2025-12-30
金城医药最新公告：与傅苗青、周白水签署股权转让协议之补充协议
金城医药(300233.SZ)两家子公司税款及滞纳金缴纳完毕
智通财经 · 2025-12-28
金城医药(300233.SZ)两家子公司税款及滞纳金缴纳完毕
金城医药董事会完成董事长补选及高管聘任
中金财经 · 2025-12-26
金城医药董事会完成董事长补选及高管聘任
金城医药：截至2025年12月20日股东总户数为27,549户
证券之星 · 2025-12-24
金城医药：截至2025年12月20日股东总户数为27,549户
金城医药(300233.SZ)实控人赵叶青收到行政处罚决定书
智通财经 · 2025-12-11
金城医药(300233.SZ)实控人赵叶青收到行政处罚决定书
金城医药：截至2025年12月10日股东户数为26,997户
证券之星 · 2025-12-11
金城医药：截至2025年12月10日股东户数为26,997户
金城医药：截至2025年11月30日股东户数为27,320户
证券之星 · 2025-12-02
金城医药：截至2025年11月30日股东户数为27,320户
加载更多
公司概况
公司名称：
山东金城医药集团股份有限公司
所属行业：
医药制造业
上市日期：
2011-06-22
主营业务：
山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是头孢侧链活性酯系列产品、生物制药及特色原料药、制剂以及其他医药化工产品。
发行价格：
18.60
{"stockData":{"symbol":"300233","market":"SZ","secType":"STK","nameCN":"金城医药","latestPrice":15.3,"timestamp":1770361386000,"preClose":15.19,"halted":0,"volume":5672970,"delay":0,"changeRate":0.0072,"floatShares":372000000,"shares":384000000,"eps":0.2014,"marketStatus":"已收盘","change":0.11,"latestTime":"02-06 15:00:00","open":15.17,"high":15.43,"low":15.1,"amount":86961500,"amplitude":0.0217,"askPrice":15.3,"askSize":448,"bidPrice":15.29,"bidSize":147,"shortable":0,"etf":0,"ttmEps":0.2014,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":15.19,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":16.71,"lowLimit":13.67,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":383874587,"isCdr":false,"pbRate":1.6,"roa":"--","peRate":75.968222,"roe":"0.85%","epsLYR":0.52,"committee":-0.030271,"marketValue":5873000000,"turnoverRate":0.0153,"status":0,"floatMarketCap":5687000000},"requestUrl":"/m/hq/s/300233","defaultTab":"news","newsList":[{"id":"2608885105","title":"股市必读：金城医药（300233）预计2025年全年归属净利润盈利4000万元至5300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608885105","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608885105?lang=zh_cn&edition=full","pubTime":"2026-02-02 01:32","pubTimestamp":1769967131,"startTime":"0","endTime":"0","summary":"业绩披露要点金城医药发布业绩预告，预计2025年全年归属净利润盈利4000万元至5300万元。公司公告汇总山东金城医药集团股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为4,000万元至5,300万元，比上年同期下降79.67%至73.07%；扣除非经常性损益后的净利润为2,800万元至3,700万元，同比下降84.44%至79.43%。非经常性损益对净利润影响为1,200万元至1,600万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200000721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"gpt_icon":0},{"id":"2607019895","title":"金城医药：预计2025年全年扣非后净利润盈利2800万元至3700万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607019895","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607019895?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:18","pubTimestamp":1769768335,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药发布业绩预告，预计2025年全年扣非后净利润盈利2800万元至3700万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000034187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"gpt_icon":0},{"id":"2606246712","title":"金城医药（300233）披露签署权益许可和经销协议之补充协议，1月26日股价上涨2.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246712","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606246712?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:24","pubTimestamp":1769437483,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，金城医药报收于16.25元，较前一交易日上涨2.91%，最新总市值为62.38亿元。金城医药于2026年1月26日发布《关于签署权益许可和经销协议之补充协议的公告》。公告显示，山东金城医药集团股份有限公司与Theramex签署《权益许可和经销协议之补充协议1》，获得利塞膦酸钠片、利塞膦酸钠肠溶片、雌二醇贴片等产品在中国境内的独家排他商业化权益。金城医药负责注册、分销、市场推广及监管事务，Theramex作为上市许可持有人供货。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600035819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2606213146","title":"金城医药与Theramex深化合作，再获五款女性健康产品中国独家权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2606213146","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606213146?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:00","pubTimestamp":1769418021,"startTime":"0","endTime":"0","summary":"中访网数据 山东金城医药集团股份有限公司今日公告，公司与英国女性健康药物公司Theramex HQ UK Limited签署了《权益许可和经销协议之补充协议1》，进一步深化双方在女性健康领域的战略合作。Theramex将继续作为产品在上述区域的上市许可持有人，金城医药则作为指定代理人，负责合作产品的注册、分销、市场推广及相关监管事务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260126/31972576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","FHCO","300233","BK0028"],"gpt_icon":0},{"id":"2605108273","title":"金城医药最新公告：子公司金城金素收到注射用头孢呋辛钠药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2605108273","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605108273?lang=zh_cn&edition=full","pubTime":"2026-01-21 18:14","pubTimestamp":1768990453,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司控股子公司广东金城金素制药有限公司收到国家药品监督管理局下发的注射用头孢呋辛钠《药品补充申请批准通知书》。该药品为公司原研药地产化产品，适用于多种细菌引起的感染，并可用于外科手术中的感染预防。此次质量标准的修订对产品质量提升有积极意义，但药品销售受政策和市场环境影响，投资者需注意相关风险。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260121/31960680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2605724521","title":"金城医药：截至2026年1月20日股东总户数为29,110户","url":"https://stock-news.laohu8.com/highlight/detail?id=2605724521","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605724521?lang=zh_cn&edition=full","pubTime":"2026-01-21 16:57","pubTimestamp":1768985863,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司截止到一月二十日股东人数是多少？金城医药回复：投资者，您好，截至2026年1月20日，公司股东总户数为29,110户。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100027415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2602518870","title":"金城医药控股股东金城实业质押展期，涉及178.64万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602518870","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602518870?lang=zh_cn&edition=full","pubTime":"2026-01-12 17:23","pubTimestamp":1768209791,"startTime":"0","endTime":"0","summary":"中访网数据 山东金城医药集团股份有限公司于2026年1月12日发布公告，其控股股东淄博金城实业投资股份有限公司对其持有的部分公司股份办理了质押展期。本次展期涉及股份数量为1,786,400股，占公司总股本的0.47%，占金城实业所持股份的2.27%。公司强调，本次操作仅为质押展期，不涉及新增融资。截至公告日，金城实业及其一致行动人合计持有公司24.08%的股份，其中处于质押状态的股份为17,588,900股，占其合计持股的19.02%，占公司总股本的4.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260112/31934721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2602391845","title":"股市必读：金城医药（300233）1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602391845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602391845?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:04","pubTimestamp":1767891853,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，金城医药报收于14.79元，上涨2.71%，换手率3.25%，成交量12.1万手，成交额1.78亿元。董秘最新回复投资者： 1，2025年核定的烟碱生产量为200吨是否能满足公司的国内外客户需求量？后续公司也将结合行业政策、市场变化及自身战略发展规划，加强产品创新及市场布局，不断提高市场竞争力。当日关注点来自交易信息汇总：1月8日主力资金净流入2406.34万元，显示主力对金城医药股票的积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900000779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"gpt_icon":0},{"id":"2601933678","title":"金城医药(300233)12月31日股东户数2.77万户，较上期增加0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601933678","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601933678?lang=zh_cn&edition=full","pubTime":"2026-01-06 17:38","pubTimestamp":1767692331,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2025年12月31日公司股东户数为2.77万户，较12月20日增加187.0户，增幅为0.68%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至12月31日，化学制药行业平均股东户数为3.44万户。从股价来看，2025年12月20日至2025年12月31日，金城医药区间跌幅为3.58%，在此期间股东户数增加187.0户，增幅为0.68%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600029622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2600308060","title":"每周股票复盘：金城医药（300233）子公司补缴税款影响净利减少993.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600308060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600308060?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:36","pubTimestamp":1767382574,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，金城医药报收于13.99元，较上周的14.29元下跌2.1%。公司公告汇总山东金城医药集团股份有限公司控股子公司广东金城金素制药有限公司及全资子公司广东榄都药业有限公司因2017年和2018年纳税情况被查，需补缴税款及滞纳金合计2,159.68万元，目前已缴纳完毕，不涉及行政处罚。公司拟依据股权转让协议向原股东追偿，若未能全额追回，预计对公司当期归属于上市公司股东的净利润影响为-993.13万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2595671898","title":"金城医药（300233）披露签署《股权转让协议》之补充协议，12月30日股价下跌1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595671898","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595671898?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:14","pubTimestamp":1767104060,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，金城医药报收于14.02元，较前一交易日下跌1.06%，最新总市值为53.82亿元。该股当日开盘14.2元，最高14.2元，最低13.88元，成交额达8740.32万元，换手率为1.68%。近日，金城医药第六届董事会第二十次会议审议通过《关于签署<股权转让协议>之补充协议的议案》。公司与傅苗青、周白水就金城金素及榄都药业补缴税款事项签署补充协议。乙方应在收到通知后10日内配合完成股权转让及工商变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000043886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2595740797","title":"金城医药最新公告：子公司金城泰尔收到药品GMP符合性检查告知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2595740797","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595740797?lang=zh_cn&edition=full","pubTime":"2025-12-30 21:21","pubTimestamp":1767100885,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司全资子公司金城泰尔收到北京市药品监督管理局核准签发的《药品GMP符合性检查告知书》，其申报的米拉贝隆原料药已通过《药品生产质量管理规范（2010年修订）》符合性检查。此次获得药品GMP符合性检查告知书丰富了公司产品种类，有利于提升在化学原料药领域的市场竞争力。金城泰尔将按照相关要求和市场需求开展生产。但需注意，药品的生产、销售等具体情况存在不确定性，投资者需注意风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000042199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2595779789","title":"金城医药：不存在退市风险警示情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2595779789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595779789?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:52","pubTimestamp":1767099160,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)12月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司会不会退市，最新一期的股东户是金城医药回复：投资者，您好，根据相关规定，目前公司不存在触及财务类、交易类、规范类或重大违法类退市风险警示的情形。截至2025年12月20日公司股东总户数为27,549户，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000040865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2595562793","title":"金城医药最新公告：与傅苗青、周白水签署股权转让协议之补充协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2595562793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595562793?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:33","pubTimestamp":1767087213,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司与傅苗青、周白水就金城金素及榄都药业补缴税款情况签署《补充协议》，修订了原协议中关于税款追缴责任的条款，由乙方向甲方以其持有的浙江磐谷药源有限公司的股权补偿甲方因金城金素或目标公司被追缴税款、滞纳金和罚款等遭受的所有损失。此外，双方还就补偿股权的价值评估、赔偿责任的确定及履行、争议解决及其他约定等内容进行了明确。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000029144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"gpt_icon":0},{"id":"2594122161","title":"金城医药(300233.SZ)两家子公司税款及滞纳金缴纳完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2594122161","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594122161?lang=zh_cn&edition=full","pubTime":"2025-12-28 16:23","pubTimestamp":1766910218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金城医药(300233.SZ)公告，公司控股子公司广东金城金素制药有限公司(“金城金素”)及其全资子公司广东榄都药业有限公司(“榄都药业”)近期分别收到国家税务总局中山市税务局下发的《税务处理决定书》。根据税务部门对金城金素及榄都药业2017年和2018年纳税情况的检查，金城金素及榄都药业应补缴税款及滞纳金共计2159.68万元。截至本公告披露日，金城金素及榄都药业的税款及滞纳金已缴纳完毕。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300233","BK0028"],"gpt_icon":0},{"id":"2594298745","title":"金城医药董事会完成董事长补选及高管聘任","url":"https://stock-news.laohu8.com/highlight/detail?id=2594298745","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594298745?lang=zh_cn&edition=full","pubTime":"2025-12-26 18:19","pubTimestamp":1766744386,"startTime":"0","endTime":"0","summary":"中访网数据 山东金城医药集团股份有限公司于2025年12月26日召开第六届董事会第十九次会议，审议通过了多项重要人事任命。会议选举产生了新任董事长，并对董事会专门委员会成员进行了相应补选。同时，董事会决议聘任了新的高级管理人员及董事会秘书。上述所有议案均获得与会董事全票通过，相关人员的任职资格已事先经公司董事会提名委员会审查通过。此次人事变动标志着金城医药公司治理结构的一次重要调整，相关任命将影响公司未来的战略决策与日常运营管理。公司表示，本次会议的召集、召开及表决程序均符合《公司法》及《公司章程》的规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251226/31895235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","300233","BK0239"],"gpt_icon":0},{"id":"2593422889","title":"金城医药：截至2025年12月20日股东总户数为27,549户","url":"https://stock-news.laohu8.com/highlight/detail?id=2593422889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593422889?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:04","pubTimestamp":1766559863,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月20日股东人数是多少？金城医药回复：投资者，您好，截至2025年12月20日公司股东总户数为27,549户，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2590659179","title":"金城医药(300233.SZ)实控人赵叶青收到行政处罚决定书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590659179","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590659179?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:51","pubTimestamp":1765446684,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金城医药 公告，公司2025年12月10日收到实际控制人赵叶青先生的通知，其收到中国证监会《行政处罚决定书》。公告显示，2017年8月18日至2020年2月10日，赵叶青、王震、刘峰3人共同操纵“金城医药”股票。中国证监会决定：一、依据2005年《证券法》第二百零三条的规定，对赵叶青、王震、刘峰处以300万元罚款，其中赵叶青承担150万元，王震承担120万元，刘峰承担30万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"金城医药(300233.SZ)实控人赵叶青收到行政处罚决定书","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2590598961","title":"金城医药：截至2025年12月10日股东户数为26,997户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590598961","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590598961?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:42","pubTimestamp":1765438929,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月10日公司股东人数是多少？金城医药回复：投资者，您好，截至2025年12月10日公司股东总户数为26,997户，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100019727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"gpt_icon":0},{"id":"2588702993","title":"金城医药：截至2025年11月30日股东户数为27,320户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702993?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:57","pubTimestamp":1764637035,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至11月30日公司的股东人数是多少？谢谢金城医药回复：投资者，您好，截至2025年11月30日公司股东总户数为27,320户，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770595401842,"stockEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":0.0625},{"period":"3month","weight":-0.1074},{"period":"6month","weight":-0.1352},{"period":"1year","weight":0.2208},{"period":"ytd","weight":0.0936}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东金城医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"29110人(较上一季度增加4.95%)","perCapita":"12768股","listingDate":"2011-06-22","address":"山东省淄博市淄川区经济开发区双山路1号","registeredCapital":"38387万元","survey":" 山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是头孢侧链活性酯系列产品、生物制药及特色原料药、制剂以及其他医药化工产品。","listedPrice":18.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金城医药,300233,金城医药股票,金城医药股票老虎,金城医药股票老虎国际,金城医药行情,金城医药股票行情,金城医药股价,金城医药股市,金城医药股票价格,金城医药股票交易,金城医药股票购买,金城医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}